Financial Tear Sheet

Corporate Profile

Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones. In October 2010, the U.S. Food and Drug Administration (FDA) approved NUEDEXTA®, a unique proprietary combination of ... More >>

Investor Relations

Ian Clements, PhD
Avanir Pharmaceuticals
Phone: (949) 389-6700
E-mail: ir@avanir.com

Stock Performance

AVNR (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	$3.25
Change (%)	▼ 0.02 (0.61%)
Volume	769,240
52 Week Low	$2.07
Market Cap	$471,604,250
Rolling EPS	-0.41
PE Ratio	N/A
Shares Outstanding	145,109,000

Data as of 05/22/13 4:00 p.m. ET

Recent Headlines & Events

05/22/13 - 9:00 a.m.
Avanir Pharmaceuticals to Participate in Two Upcoming Investor Conferences

05/08/13 - 4:01 p.m.
Avanir Pharmaceuticals Reports Fiscal 2013 Second Quarter Financial and Business Results

05/01/13 - 8:31 a.m.
Avanir Pharmaceuticals Announces Date of Fiscal 2013 Second Quarter Financial Results and Conference Call

American Psychiatric Association
Saturday, May 18, 2013 through Wednesday, May 22, 2013
Location San Francisco, CA

Avanir Pharmaceuticals at Deutsche Bank 38th Annual Health Care Conference
Wednesday, May 29, 2013 12:00 p.m. ET
Location Boston, MA

Avanir Pharmaceuticals at Jefferies Global Healthcare Conference
Monday, June 3, 2013 8:30 a.m. ET
Location New York City, NY US

National Association Director of Nurse Administration
Saturday, June 8, 2013 through Wednesday, June 12, 2013
Location Las Vegas, NV

Alzheimer's Association International Congress
Saturday, July 13, 2013 through Thursday, July 18, 2013
Location Boston, MA

Gerontological Advanced Practice Nurses Association
Wednesday, September 18, 2013 through Saturday, September 21, 2013
Location Chicago, IL

Analyst Estimates / Ratings

Mean Recommendation: 1.6

Sell — Strong Buy

EPS Trend

		Current	30 Days Ago	90 Days Ago
QTR	Jun 13	-0.09	-0.07	-0.07
QTR	Sep 13	-0.08	-0.02	-0.02
QTR	Dec 13	-0.04	-0.04	-0.04
QTR	Mar 14	-0.02	-0.03	-0.03
FY	Sep 13	-0.37	-0.26	-0.26
FY	Sep 14	-0.09	-0.05	-0.05

Management

Keith A. Katkin	President & Chief Executive Officer
Gregory J. Flesher	Senior Vice President, Corporate Development & Chief Business Officer
Randall E. Kaye, M.D.	Senior Vice President, Medical Affairs & Chief Medical Officer
Joao Siffert, M.D.	Senior Vice President, Research & Development
Eric S. Benevich	Vice President, Marketing
Adrian Hepner, M.D.	Vice President, Clinical Research
Elona Kogan, Esq.	Vice President, Legal Affairs
Michael E. McFadden	Vice President, US Sales and Managed Markets
Christine G. Ocampo, CPA	Vice President, Finance

Board of Directors

Hans E. Bishop	Independent Director
Keith A. Katkin	Inside Director
David J. Mazzo, Ph.D.	Independent Director
Corinne Nevinny	Independent Director
Dennis G. Podlesak	Independent Director
Craig A. Wheeler	Independent Director
Scott M. Whitcup, M.D.	Independent Director

SEC Filings

Filing Date	Form	Description
05/17/13	4	Statement of changes in beneficial ownership of securities
05/17/13	4	Statement of changes in beneficial ownership of securities
05/09/13	10-Q	Quarterly report which provides a continuing view of a company's financial position
05/08/13	8-K	Report of unscheduled material events or corporate event

Ownership Summary

Shareholders

	Holders	Value ($MM)	% O/S	Shares
Institution	114	277.88	69.6	100,980,946
Mutual Fund	159	150.20	37.7	54,746,966
Insider *	41	83.02	17.2	25,005,286

*Insider values reflect direct beneficial ownership.

Top Holders

	Shares Held	% O/S	Share Change	Filing Date
T. Rowe Price Associates, Inc.	21,939,011	15.1	101,100	03/31/13
Fidelity Management & Research Company	15,719,656	10.8	1,463,000	03/31/13
Ingalls & Snyder LLC (Asset Management)	12,698,157	8.8	-552,378	03/31/13
Wellington Management Company, LLP	9,978,300	6.9	1,790,556	03/31/13
BlackRock Institutional Trust Company, N.A.	8,870,755	6.1	654,122	03/31/13
The Vanguard Group, Inc.	5,398,867	3.7	-1,716,837	03/31/13
Invus Public Equities Advisors, LLC	3,519,927	2.4	536,427	03/31/13
TimesSquare Capital Management, LLC	3,356,160	2.3	-113,800	03/31/13
State Street Global Advisors (US)	3,036,561	2.1	-36,164	03/31/13
Adage Capital Management, L.P.	2,300,000	1.6	1,100,000	03/31/13

Powered By EDGAR Online

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Minimum 20 minutes delayed